SCHEDULE 13G/A: Deep Track Capital Divests Entire Stake in Editas Medicine, Filing Shows Zero Beneficial Ownership
Beneficial Ownership Report Amendment
Deep Track Capital, LP and its affiliates have reported a complete divestment of their beneficial ownership in Editas Medicine, Inc., holding 0% of the common stock as of December 31, 2024.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their holdings in Editas Medicine, Inc.
- As of December 31, 2024, the Reporting Persons collectively hold 0.00 shares of Editas Medicine's Common Stock, representing 0.00% of the class.
- This filing indicates a complete divestment of their previous beneficial ownership in the company.
- The percentage of class is calculated based on 82,548,099 Common Stock outstanding as of October 30, 2024, as reported in Editas Medicine's 10-Q filing on November 4, 2024.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 3
Explanation: The complete divestment by an institutional investor is a negative signal, indicating a lack of confidence or a shift in investment strategy regarding the issuer.
Negatives
- Deep Track Capital, a significant institutional investor, has fully divested its stake in Editas Medicine, which can be perceived negatively by the market.
Risks
- The complete divestment by an institutional investor like Deep Track Capital could signal a lack of confidence in Editas Medicine's future prospects, potentially impacting investor sentiment and stock price.
Future Outlook
This document does not contain any forward-looking statements or guidance regarding Editas Medicine's future outlook.
Industry Context
This filing reflects a change in an institutional investor's position in a biotechnology company. In the biotech sector, investor confidence and institutional holdings can significantly influence stock performance, especially for companies like Editas Medicine that are often in the research and development phase.
Stakeholder Impact
- Shareholders: The divestment by a significant institutional investor could lead to decreased investor confidence and potential downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 2024-10-30 | Date as of which 82,548,099 Common Stock of Editas Medicine were outstanding, according to the issuer's 10-Q. |
| 2024-11-04 | Date Editas Medicine's 10-Q was filed with the SEC, reporting shares outstanding. |
| 2024-12-31 | Date of event which requires filing of this statement, indicating the effective date of the 0% beneficial ownership. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Editas Medicine, Deep Track Capital, Beneficial Ownership, Schedule 13G, SEC Filing, Divestment, Institutional Investor, Common Stock, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.